- Trials with a EudraCT protocol (3,215)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
3,215 result(s) found for: Safety case.
Displaying page 1 of 161.
EudraCT Number: 2012-005716-26 | Sponsor Protocol Number: 110021 | Start Date*: 2015-06-17 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase III, double blind (observer-blind), randomized, controlled multi-center study to evaluate, in infants and children, the efficacy of the RTS,S/AS01E candidate vaccine against malaria disease... | ||
Medical condition: Healthy volunteers (Primary and booster immunization against Plasmodium falciparum malaria) | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2012-000721-53 | Sponsor Protocol Number: ITT-PMSExt | Start Date*: 2012-12-07 | |||||||||||
Sponsor Name:Dept of Neurology, Umeå University Hospital, Umeå, Sweden | |||||||||||||
Full Title: ITT-PMS Extension An extension study of intrathecal therapy with monoclonal antibodies in progressive multiple sclerosis | |||||||||||||
Medical condition: Secondary progressive multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000525-60 | Sponsor Protocol Number: 750801.01.017 | Start Date*: 2006-06-09 |
Sponsor Name:Dr. Willmar Schwabe GmbH & Co. KG | ||
Full Title: Multi-center, double-blind, placebo-controlled, randomized phase III study to demonstrate the efficacy and investigate the safety of Hypericum extract WS® 5570 in patients with a Major Depressive E... | ||
Medical condition: Major depressive episode according to DSM-IV (single episode: 296.22, recurrent episode: 296.32; duration at least two weeks but not longer than one year). | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-017458-11 | Sponsor Protocol Number: DEP-HOM | Start Date*: 2010-06-10 |
Sponsor Name:Institute for Social Medicine, Epidemiology, and Health Economics, Charité Berlin | ||
Full Title: Homeopathy for Depression: a randomized, four-armed, partial double-blind study. | ||
Medical condition: F32.1 Moderate Depressive Episode | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2013-002886-20 | Sponsor Protocol Number: DHNS2013-01/MOHN01 | Start Date*: 2014-01-30 |
Sponsor Name:UMC St Radboud | ||
Full Title: A phase Ib-II study of the combination of cetuximab and methotrexate in recurrent or metastatic squamous cell carcinoma of the head and neck. A study of the Dutch Head and Neck Society. | ||
Medical condition: Recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2024-000442-10 | Sponsor Protocol Number: A8081056 | Start Date*: 2024-10-11 |
Sponsor Name:Pfizer, Inc | ||
Full Title: CRIZOTINIB (XALKORI(REGISTERED)) EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF ADULT OR PEDIATRIC PATIENTS WITH SOLID OR HEMATOLOGIC MALIGNANCIES THAT HARBOR A CRIZOTINIB-SENSITIVE MOLECULAR ALTERA... | ||
Medical condition: Solid tumors | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2021-002966-41 | Sponsor Protocol Number: APHP210639 | Start Date*: 2021-08-13 | |||||||||||
Sponsor Name:Assistance Publique – Hôpitaux de Paris / DRCI | |||||||||||||
Full Title: Anti-Covid-19 vaccine protection in immunocompromised children (1-15 years) with acute leukemia and their siblings (≥ 12 years). Phase I-II trial evaluating safety and post-vaccination humoral and ... | |||||||||||||
Medical condition: - Children aged 1-15 years with LA undergoing chemotherapy or whose last chemotherapy session date is less than or equal to 12 months. - Siblings of children with LA (living in the same household... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023185-42 | Sponsor Protocol Number: S105AMCNilotinibSpA | Start Date*: 2011-04-21 |
Sponsor Name:Academic Medical Center, Division of Clinical Immunology and Rheumatology | ||
Full Title: Proof-of-concept double-blind, placebo-controlled, randomized clinical trial with nilotinib in spondyloarthritis | ||
Medical condition: Active axial and peripheral spondyloarthritis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-003087-20 | Sponsor Protocol Number: 800_OPBG_2014 | Start Date*: 2014-11-12 | |||||||||||||||||||||
Sponsor Name:IRCCS Ospedale Pediatrico Bambino Gesù | |||||||||||||||||||||||
Full Title: Determination of Plasmatic and CSF Levels Of High Doses Of Micafungin in Neonates Suffering from Systemic Candidiasis and/or Candida meningitis. | |||||||||||||||||||||||
Medical condition: Systemic Candidiasis and/or Candida Meningitis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-000537-35 | Sponsor Protocol Number: 07/2006 | Start Date*: 2006-08-04 |
Sponsor Name:Portuguese Lung Cancer Study Group | ||
Full Title: Open-label, Uncontrolled, Multicenter, Phase II study evaluating the efficacy and safety of Cetuximab in combination with Cisplatin & Gemcitabine as first-line therapy in patients with advanced non... | ||
Medical condition: Non small cell lung cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: PT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-004978-27 | Sponsor Protocol Number: 1-2006 | Start Date*: 2007-08-03 |
Sponsor Name:Zentralklinikum St. Pölten | ||
Full Title: Initial Combination of Photodynamic Therapy with Verteporfin and Intravitreal Administration of Ranibizumab in Patients with Subfoveal Choroidal Neovascularisation due to Age-related Macular Degene... | ||
Medical condition: The case-series is designed to evaluate the safety and efficacy of intravitreal ranibizumab used in combination with verteporfin photodynamic therapy (Visudyne) for the treatment of subfoveal CNV s... | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-006652-22 | Sponsor Protocol Number: AN08/8751 | Start Date*: 2009-06-03 |
Sponsor Name:Leeds Teaching Hospital NHS Trust | ||
Full Title: A multicentre, randomised, double blind, evaluative comparison trial of Rapydan® patch and Ametop® gel for topical anaesthesia during venous cannulation in adults admitted to hospital for day-case ... | ||
Medical condition: ASA 1 and 2 patients admitted for Day case surgery- assessment of cannulation pain after topical anaesthetic applications. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-001070-27 | Sponsor Protocol Number: EP-PAE Metalyse | Start Date*: 2005-07-07 |
Sponsor Name:Division of Angiology Graz | ||
Full Title: Open, randomised, monosite pilot trial for comparison of thrombolytic efficacy of tenecteplase and alteplase in patients with acute pulmonary embolism | ||
Medical condition: Patients with acute pulmonary embolism and indication for thrombolytic therapy are included in the study | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-006765-82 | Sponsor Protocol Number: MOXEP | Start Date*: 2009-05-29 | |||||||||||||||||||||
Sponsor Name:ISTITUTO NAZIONALE DELLE MALATTIE INFETTIVE LAZZARO SPALLANZANI | |||||||||||||||||||||||
Full Title: Preventive therapy for multidrug-resistant tuberculosis: a multicentre clincal trial. | |||||||||||||||||||||||
Medical condition: Close contacts of an infectious respiratory of a MDR-TB who are diagnosed with tuberculosis infection that is likely to have been acquired from the MDR-TB case will be eligible for inclusion in th... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021792-81 | Sponsor Protocol Number: 2010-12 | Start Date*: Information not available in EudraCT |
Sponsor Name:ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE | ||
Full Title: SFCE-Metro 01 : Etude de phase II de chimiothérapie métronomique associant celecoxib-methotrexate-vinblastine-cyclophosphamide chez les enfants porteurs d’une tumeur solide en rechute ou en progre... | ||
Medical condition: children and adolescents with relapsed or progressing solid tumours. | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-001118-15 | Sponsor Protocol Number: APL-B-005-02 | Start Date*: 2004-10-27 |
Sponsor Name:Pharma Mar, S.A | ||
Full Title: Phase II multicenter,open-label, clinical and pharmacokinetic study of Aplidin® as a 3-hour infusion every 2 weeks, in patients with advanced or metastatic transitional cell carcinoma of the uroth... | ||
Medical condition: More than 90% of bladder carcinomas are transitional cell carcinomas (TCC) derived from the uroepithelium. About 6% to 8% are squamous cell carcinomas, and 2% are adenocarcinomas. Adenocarcinomas ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-005095-17 | Sponsor Protocol Number: EA041999 | Start Date*: 2005-02-10 |
Sponsor Name:Engelhard Arzneimittel GmbH & Co. KG | ||
Full Title: Randomised, double-blind, placebo-controlled, monocentric phase III study on the efficacy and safety of Lidocaine 8 mg Sore Throat Lozenges in patients with moderate to severe acute sore throat not... | ||
Medical condition: The study will be performed in patients suffering from acute sore throat not necessarily to be treated with antibiotics | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-000904-39 | Sponsor Protocol Number: MK-4482-013 | Start Date*: 2021-08-11 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19 (Laboratory-confirmed SARS-CoV-2 Infection W... | |||||||||||||
Medical condition: Prophylaxis of COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) FR (Completed) HU (Completed) BG (Completed) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-004469-11 | Sponsor Protocol Number: PP-SA-001 | Start Date*: 2022-01-11 |
Sponsor Name:PHERECYDES PHARMA | ||
Full Title: PhagoDAIR I: A Phase I/II Multicenter, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Phage Therapy in Patients with Hip or Knee Prosthetic Joint Infection due to Staphylococcus ... | ||
Medical condition: knee or hip prosthetic joint infection (PJI) due to Staphylococcus aureus, with the indication of DAIR and Suppressive Antibiotics Therapy (SAT | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001825-28 | Sponsor Protocol Number: R119513 | Start Date*: 2019-09-24 | |||||||||||
Sponsor Name: The University of Manchester | |||||||||||||
Full Title: Mesoangioblast-mediated exon 51 skipping for genetic correction of dystrophin, based upon a single injection in individual skeletal muscles of five non ambulant patients affected by Duchenne Muscul... | |||||||||||||
Medical condition: Duchenne Muscular Dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
